SCHEMBL2686802

SCHEMBL2686802

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)Nc1cnc(-c2ccncc2)s1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 2/20 0.61
CTSS P25774 6/20 0.53
CTSK P43235 5/20 0.53
CTSB P07858 2/20 0.53
CTSL P07711 2/20 0.53
HDAC8 Q9BY41 1/20 0.49
PTPRB P23467 2/20 0.48
AKT1 P31749 1/20 0.47
PRKACA P17612 1/20 0.47
ROCK1 Q13464 1/20 0.47
ACE P12821 1/20 0.46
CCKAR P32238 2/20 0.45
CCKBR P32239 2/20 0.45
BCL2 P10415 1/20 0.45
SCN9A Q15858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686800 1.00 GPR142 (0.61) GPR142CTSSCTSKCTSBCTSL
SCHEMBL2686172 0.91 CTSS (0.53) GPR142CTSSCTSKCTSBCTSL
SCHEMBL2686171 0.91 CTSS (0.53) GPR142CTSSCTSKCTSBCTSL
SCHEMBL2684371 0.86 GPR142 (0.70) GPR142CTSLPRKACAROCK1
SCHEMBL2684697 0.85 GPR142 (0.58) GPR142CTSSCTSKCTSBCTSL
SCHEMBL2684695 0.85 GPR142 (0.58) GPR142CTSSCTSKCTSBCTSL
SCHEMBL5960021 0.82 GPR142 (0.61) GPR142CTSSCTSKCTSBCTSL
SCHEMBL28254321 0.79 CSNK2A2 (0.47) GPR142HDAC8PTPRBAKT1PRKACA
SCHEMBL2684768 0.78 GPR142 (0.64) GPR142AKT1PRKACAROCK1
SCHEMBL2684771 0.78 GPR142 (0.64) GPR142AKT1PRKACAROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885CTSS 3372/4885CTSK 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.